FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.
What happened
FDA inspected the facility from January 8 to 16, 2024. It found serious quality assurance problems, including discarded original current good manufacturing practice (CGMP) records and uncontrolled blank production records, and inadequate separation between sterile processing areas with inadequate smoke studies. FDA said the company's March 7, 2024 response was inadequate.
What FDA found
The quality control unit did not adequately oversee manufacturing quality and data reliability.
21 CFR 211.22Original CGMP records were found discarded in a bag under a vehicle and in a nearby trash can.
21 CFR 211.22The production manager accessed and printed uncontrolled blank production, validation, and cleaning records without quality assurance issuance.
21 CFR 211.22There was inadequate physical separation between Grade A and Grade B cleanroom areas for sterile drug manufacturing.
21 CFR 211.42(c)(10)The facility lacked smoke studies to show airflow between the Grade A and Grade B transition areas outside the filling machine.
21 CFR 211.42(c)(10)The transfer cart for drug vials was open on both sides, showed air turbulence, and did not monitor non-viable particles in the cart.
21 CFR 211.42(c)(10)
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.
Who should pay attention
- companies using Jiangsu Hengrui as a drug manufacturer
- buyers of sterile drug products from China
- quality teams managing contract manufacturers or suppliers
This is a summary. Read the original letter on fda.gov.